Optimizing enzyme inhibition analysis: precise estimation with a single inhibitor concentration
- PMID: 40473596
- PMCID: PMC12141731
- DOI: 10.1038/s41467-025-60468-z
Optimizing enzyme inhibition analysis: precise estimation with a single inhibitor concentration
Abstract
Enzyme inhibition analysis is essential in drug development and food processing, necessitating precise estimation of inhibition constants. Traditionally, these constants are estimated through experiments using multiple substrate and inhibitor concentrations, but inconsistencies across studies highlight a need for a more systematic approach to set experimental designs across all types of enzyme inhibition. Here, we address this by analyzing the error landscape of estimations in various experimental designs. We find that nearly half of the conventional data is dispensable and even introduces bias. Instead, by incorporating the relationship between IC50 and inhibition constants into the fitting process, we find that using a single inhibitor concentration greater than IC50 suffices for precise estimation. This IC50-based optimal approach, which we name 50-BOA, substantially reduces (>75%) the number of experiments required while ensuring precision and accuracy. Additionally, we provide a user-friendly package that implements the 50-BOA.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: The authors declare no competing interests.
Figures





Similar articles
-
Determination of Half-Maximal Inhibitory Concentration of an Enzyme Inhibitor.Methods Mol Biol. 2020;2089:41-46. doi: 10.1007/978-1-0716-0163-1_3. Methods Mol Biol. 2020. PMID: 31773646
-
Characterization of Inhibitor Binding Through Multiple Inhibitor Analysis: A Novel Local Fitting Method.Methods Mol Biol. 2016;1439:33-45. doi: 10.1007/978-1-4939-3673-1_2. Methods Mol Biol. 2016. PMID: 27316986
-
Considerations about the inhibition of monophenolase and diphenolase activities of tyrosinase. Characterization of the inhibitor concentration which generates 50 % of inhibition, type and inhibition constants. A review.Int J Biol Macromol. 2024 May;267(Pt 2):131513. doi: 10.1016/j.ijbiomac.2024.131513. Epub 2024 Apr 10. Int J Biol Macromol. 2024. PMID: 38608979 Review.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
References
-
- Manikandan, P. & Nagini, S. Cytochrome P450 structure, function and clinical significance: a review. Curr. drug targets19, 38–54 (2018). - PubMed
-
- Iyanagi, T. Molecular mechanism of phase I and phase II drug‐metabolizing enzymes: implications for detoxification. Int. Rev. Cytol.260, 35–112 (2007). - PubMed
-
- Pelkonen, O. et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol.82, 667–715 (2008). - PubMed
-
- Food, U. & Administration, D. In vitro drug interaction studies-cytochrome P450 enzyme and transporter mediated drug interactions. FDA Guid1, 1 (2020).
-
- Fahmi, O. A. et al. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab. Disposition36, 1698–1708 (2008). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources